Vaseghi Maghvan Padina, Jeibouei Shabnam, Akbari Mohammad Esmael, Niazi Vahid, Karami Farshid, Rezvani Alireza, Ansarinejad Nafiseh, Abbasinia Masroor, Sarvari Gisoo, Zali Hakimeh, Talaie Ramin
Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gastroenterol Hepatol Bed Bench. 2020 Winter;13(Suppl1):S18-S28.
Colorectal cancer (CRC) is a heterogeneous disease with various genetic and epigenetic factors leading to difficulties in response to both the therapy and drug resistance. Moreover, even in tumors with similar histopathological characteristics, different responses and molecular features could be observed because of the genetic basis and its interactions with the living environment. Through personalized medicine, we can classify patients into separate groups according to their genetic and epigenetic features and their susceptibility for a specific disease which could help with choosing the best therapeutic approach. In this review, genetic and epigenetic factors that cause heterogeneity in colorectal cancer are evaluated and proper drug administration in both chemotherapy and target therapy are suggested.
Gastroenterol Hepatol Bed Bench. 2020
World J Gastroenterol. 2014-12-14
Cancer Cell Int. 2020-1-29
Int J Environ Res Public Health. 2016-9-8
Acta Clin Belg. 2017-4
Clin Colorectal Cancer. 2016-6
Zhonghua Wei Chang Wai Ke Za Zhi. 2019-1-25
Curr Issues Mol Biol. 2025-2-12
World J Clin Oncol. 2024-9-24
J Cell Physiol. 2018-11-27
Curr Opin Oncol. 2016-7
Expert Opin Pharmacother. 2016